Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Secures Safety Advantage For TAF In HBV, Keeps Edge In HCV

This article was originally published in The Pink Sheet Daily

Executive Summary

Top-line Phase III trials support transition plan from Viread. In hepatitis C, Gilead may be further strengthening its lead with a priority review for a pan-genotypic combo pill that replaces Harvoni's ledipasvir with a more potent NS5A inhibitor.



Related Companies